Introduction
Chronic myeloid leukemia (CML) is a clonal hyperproliferative disease of the hematopoietic system developing through a multistep process. The cytogenetic hallmark of CML is the Philadelphia chromosome, which is the consequence of the translocation between chromosomes 9 and 22-t(9;22)(q34;q11). The translocation generates the chimeric gene BCR-ABL, resulting from a fusion between fragments of the genes BCR and ABL (1). The encoded protein p210BCR-ABL is a constitutively activated tyrosine kinase. The initial neoplastic transformation of the hematopoietic stem cells has been attributed to its activity (2) that leads to enhanced growth-factorindependent proliferation, inhibition of apoptosis, compromised differentiation and altered cell adhesive properties. More recent advances in CML research have also associated the activity of BCR-ABL with the disruption of genomic stability maintenance mechanisms (3) .
Thus, accumulation of acquired new mutations and cytogenetic alterations were observed in patients during the course of the disease from the initial chronic phase to the most aggressive blast crisis (4), suggesting additional activities of BCR-ABL that promote pathogenic chromosomal alterations.
DNA double-strand breaks (DSBs), which are considered the most deleterious and mutagenic type of DNA lesions, can arise spontaneously as the result of replication stress at stalled replication forks, during V(D)J immunoglobulin gene recombination and during meiosis. DSBs can also be caused by exogenous insults, such as by ionizing radiation (IR), cancer chemotherapeutic agents and reactive oxygen species (5) . The major mechanisms of DSB repair are non-homologous end joining (NHEJ), single-strand annealing (SSA) and homologous recombination (HR). Of note, these mechanisms differ with regard to the quality of the repair process, with NHEJ and SSA being highly error-prone processes and HR representing a comparatively high-fidelity DSB repair pathway. Lack of accuracy, deregulation or dysfunction of DSB repair mechanisms can result in chromosomal rearrangements like translocations, deletions and inversions (6) .
In human cells, HR requires the interaction and activation of a protein complex comprising MRE11, RAD50 and Nibrin as well as adaptor proteins like 53BP1 and MDC1 for recognition of DSBs and activation of the signaling cascades that lead to effective repair (7, 8) . DNA end processing, which may be catalyzed by CtIP, as it was shown to function as a nuclease in vitro, leads to the formation of single-stranded DNA (ssDNA) tails that will be engaged in strand exchange with a homologous template by the strand transferase RAD51 (6, 9) .
NHEJ involves the simple religation or the alignment of broken DNA ends without the use of extensive homology. During processing of non-compatible DNA ends, NHEJ introduces mutations. Recently, two distinct subpathways of NHEJ have been described: the canonical and the alternative pathways also referred to as microhomologymediated end joining (MMEJ) (10) . Although the canonical pathway requires no or only minimal processing of DNA ends and employs the end-binding Ku70/80 heterodimer together with the kinase DNAPKcs as well as the ligase complex XRCC4/LigaseIV, the alternative pathway requires microhomologous sequences for the formation of the repair junction and seems to be independent of these proteins (11) (12) (13) . Even though LigaseIII and Poly(ADP-ribose)polymerase 1 (PARP1) have been implicated in MMEJ, the precise mechanism remains to be fully described (10) .
SSA is a non-conservative homology-directed DSB repair process that shares components with both NHEJ and HR (13) . SSA starts with the resection of DNA ends and formation of extensive single-stranded overhangs on DNA ends, probably mediated by CtIP in conjunction with the MRE11/RAD50/Nibrin protein complex, followed by annealing of homologous sequences in the exposed strands (9, 14) . RAD52 binds the ssDNA ends to facilitate DNA pairing (15). Unpaired heterologous overhangs are then removed by ERCC1/XPF nuclease, thereby causing loss of sequence information between the annealed repeat sequences (15, 16) .
The role of BCR-ABL in these processes has started to become deciphered, although many data remain controversial. Previous work from a number of groups had suggested an influence of BCR-ABL activity on SSA (17, 18) , NHEJ (19, 20) and HR (21) (22) (23) (24) (25) . However, it remained unclear which components of these pathways are involved in the genomic destabilization promoted by BCR-ABL, and how these pathways are modulated by these components.
In order to determine the status of DSB repair in BCR-ABL-positive human cell lines, we measured DSB repair frequencies with the help of a fluorescence-based assay engaging DNA substrates designed to analyze different DSB repair mechanisms. To identify potential BCR-ABL's targets in DSB repair, we checked key proteins involved in the relevant processes, namely MDC1, 53BP1 and CtIP. We have found that BCR-ABL-positive cell lines display enhanced mutagenic DNA repair, with a major contribution of SSA to homologous DSB repair processes. The putative DNA-end-processing nuclease CtIP was found to be implicated in the upregulation of SSA by BCR-ABL.
Materials and methods

Cell lines and treatments
The human megakaryocytic cell line Mo7e and the Mo7e.BCR-ABL (MBA) subclone stably re-expressing BCR-ABLp210 were cultivated in RPMI1640 supplemented with 15% fetal calf serum, 2% L-glutamine and 1% penicillin/ streptomycin. Ten nanograms per milliliter of granulocyte-macrophagecolony stimulating factor was added to Mo7e cultures. The K562(D3#) cell line, a subclone derived from the human myeloid leukemia cell line K562 via stable chromosomal integration of the DSB repair substrate D-enhanced green fluorescent protein (EGFP)/3#-EGFP (26) , was grown in RPMI1640 supplemented with 12% fetal calf serum, 2% L-glutamine and the antibiotic Refobacin.
To generate DSBs, Mo7e and MBA were irradiated with a dose of 6 Gy, treated with 40 U of the radiomimetic drug bleomycin or 250 ng/ml of the cross-linking agent Mitomycin C. To block the tyrosine kinase activity of BCR-ABL, the cells were treated with 0.1-1.0 lM of the small molecule class inhibitory drug, Imatinib Mesylate (IM) (Novartis Pharma, Basel, Switzerland). IM specifically inhibits BCR-ABL's tyrosine kinase activity by competing with adenosine triphosphate for its binding site in the tyrosine kinase domain (27) .
DSB repair and knockdown assays
To analyze the different mechanisms of DSB repair, we have used the EGFPbased system as described in ref. (26) . Briefly, Mo7e and MBA cells were transfected by electroporation with a mixture of one of the DNA substrates 5#EGFP/HR-EGFP, D-EGFP/3#EGFP, EJ-EGFP, D-EGFP/5#EGFP or HR-EGFP/5#EGFP, meganuclease expression plasmid DNA (pCMV-I-SceI) and pBS (control filler plasmid). DSB repair frequencies were determined by flow cytometry as the fraction of green fluorescent cells within the total cell population. To quantify EGFP reconstitution in K562(D3#) cells, electroporation mixtures contained pCMV-I-SceI and pBS. Each measurement was accompanied by the analysis of split samples after electroporation with the same plasmid mixture but including wild-type EGFP plasmid instead of pBS control plasmid. The fraction of EGFP-positive cells obtained in these controls was determined as transfection efficiency and was used to normalize the corresponding recombination frequency each. EGFP positivity was quantified by flow cytometry using a FACSÒ Calibur FACScan (Becton & Dickinson, Heidelberg, Germany).
To downregulate the expression of specific proteins during repair measurements, small hairpin RNA expression constructs directed against CtIP, MDC1 or 53BP1 were cotransfected with the DNA plasmid substrates. To inactivate endogenous RAD51, cells were cotransfected with control or pcDNA3.1-Rad51SM plasmids, as described in refs (28, 29) .
The statistical significance of differences was determined using Student's t-test for unpaired samples.
Determination of apoptosis and cell cycle distribution Apoptosis induction and cellular cell cycle distribution were obtained by FACS analysis on fixed and propidium-iodide-stained cells, precisely under the conditions of the DSB repair measurements, as described in ref. (29) .
Protein extraction and immunoblotting
Protein extracts were obtained as described previously and subjected to immunblotting (29, 30) 
Immunofluorescense
Quantitative immunfluorescence analysis was performed essentially as described in ref. (29) . Briefly, cells were spun onto cytospin glass slides, fixed in 3.7% (vol/vol) formaldehyde and permeabilized in 0.5% Triton X-100 followed by blocking with 5% goat serum in phosphate-buffered saline. For replication protein A (RPA) foci visualization, a pre-extraction procedure was applied before fixation by incubation in pre-extraction solution (9) . Immunostaining was carried out with the antibodies anti-RPA (Calbiochem, Darmstadt, Germany) or anti-53BP1 (Novus Biologicals, Littleton, CO) and secondary antibodies were conjugated with Alexa555 (Invitrogen, Darmstadt, Germany). Nuclei were stained with 4#,6-diamidino-2-phenylindole. Nuclear structures were visualized by an Olympus BX51 epifluorescence microscope, photographed by an Olympus XC10 camera and analyzed by CellF 2.5Ò analysis software including the mFIP software (Olympus Soft Imaging System, Münster, Germany).
Results
BCR-ABL-positive cells display elevated frequencies of error-prone DSB repair
In previous studies, a potential effect of BCR-ABL on DSB repair was examined regarding individual pathways (17) (18) (19) 21) . In order to more systematically analyze the influence of the expression of the oncoprotein BCR-ABL on DSB repair in human cell lines, we used an EGFPbased test system for the comparative analysis of different DSB repair mechanisms. DNA repair is triggered by DSB formation in vivo by the expression of meganuclease I-SceI, which introduces a single DSB at its recognition sequence within the repair substrate. To discriminate between different DSB repair pathways, we applied DNA substrates enabling the individual analysis of MMEJ (EJ-EGFP), SSA (5#EGFP/ HR-EGFP), HR (HR-EGFP/5#EGFP, D-EGFP/5#EGFP) as well as overall homology-directed DSB repair, i.e. SSA and HR (D-EGFP/ 3#EGFP) ( Figure 1A ). To exclude possible indirect effects on DSB repair related to differences in transfection, growth or cell lethality, we performed identical cotransfections including wild-type EGFP control plasmid in parallel. The resulting individual transfection efficiencies served to normalize each single DSB repair frequency.
In the present study, we used the isogenic human cell lines Mo7e and Mo7e.BCR-ABL (MBA), differing in the expression of the stably transfected p210BCR-ABL gene in MBA. Both were transfected with the DNA repair substrates and expression plasmid for the meganuclease I-SceI. As shown in Figure 1B , the frequencies of DSB repair in MBA were enhanced 3.0-fold (P 5 0.0291) for MMEJ, 2.2-fold (P 5 0.0125) for SSA and 2.3-fold (P 5 0.0218) for homologous DSB repair (HR þ SSA) in comparison with the frequencies obtained in Mo7e cells. On the other hand, the frequencies of HR with both long (P 5 0.7793) and short homologies (P 5 0.9913) were similar in Mo7e and MBA cells.
To further delineate the homologous DSB repair mechanisms affected by BCR-ABL, we engaged the DSB repair substrate D-EGFP/ 3#EGFP, which promotes both HR and SSA, in combination with inactivation of RAD51, i.e. the central strand transferase of HR. For this purpose, we applied a method previously well established on BCR-ABL-positive human cells (28, 29) . Thus, Mo7e and MBA cells were cotransfected with vector pcDNA3.1-Rad51SM encoding dominant-negative RAD51 (RAD51SM), DSB repair substrate D-EGFP/3#EGFP and I-SceI expression plasmid. As depicted in Figure 1C , the expression of RAD51SM caused a reduction by 76% of DSB repair in Mo7e (P 5 0.023), whereas no significant change was observed in MBA cells. This finding revealed that HR was the homologous DSB repair pathway predominating in Mo7e, whereas HR did not significantly contribute to the augmented DSB repair activities in MBA cells. Altogether, these results suggested that BCR-ABL upregulates pathways of error-prone DSB repair (SSA and MMEJ) but did not affect the high-fidelity mechanism of HR. Moreover, treatment of MBA cells with the BCR-ABL kinase inhibitory compound IM abrogated the increase in SSA frequencies detected in MBA compared with Mo7e cells ( Figure 1D ). This result indicated that phosphorylation of downstream targets is necessary for the effect of BCR-ABL on DSB repair.
Since phosphorylation of RAD51 by BCR-ABL had been reported to be essential for enhanced DSB repair (21) on the one hand and enhancement of RAD51-independent SSA on the other (17,18), we sought to determine the role of the BCR-ABL kinase in homologous DSB repair in another experimental system. Therefore, we utilized K562(D3#) cells, a well-characterized derivative of the
BCR-ABL-expressing human myeloid leukemia cell line K562, which carries stably integrated D-EGFP/3#EGFP DSB repair substrate (26) . K562(D3#) cells were treated with 0.1 lM, 0.25 lM and 0.5 lM of IM for 24 h, followed by transfection with I-SceI expression plasmid. Moreover, given that BCR-ABL also regulates checkpoint activation and apoptosis induction (31) , to exclude a potential influence from these end points on DSB repair, we performed corresponding DSB repair experiments with increasing IM concentrations in the presence of the pancaspase inhibitor ZVAD-fmk. The results indicated a dose-dependent decline of DSB repair reaching statistical significance at 0.25 lM IM (P 5 0.0257) and a further decrease at 0.5 lM IM (P 5 0.0089). DSB repair frequencies did not differ between ZVAD-fmk-and mock-treated cells with or without IM exposure ( Figure 2A ). The fraction of cells with a sub-G 1 DNA content ( Figure 2B ), indicative of apoptosis, showed a statistically significant difference between ZVAD-fmk-and mock-treated cells only at the highest IM concentration of 0.5 lM (P 5 0.0148). The distribution of the cells in the cell cycle ( Figure 2C ) was neither significantly altered upon ZVAD-fmk nor upon IM exposure. These data made indirect effects of BCR-ABL on DSB repair through altered growth or cell death rather unlikely. In the following experiments, we chose to apply a concentration of 0.25 lM IM, at which significantly altered DSB repair frequencies had been observed, without significant changes in the fraction of cells in apoptosis or the cell cycle.
To determine the contribution of RAD51-dependent HR to BCR-ABL-stimulated homologous DSB repair in K562(D3#), the cells BCR-ABL stimulates mutagenic homologous DNA DSB were treated with IM or left untreated and dominant-negative RAD51 (RAD51SM) was expressed together with the DSB trigger I-SceI. As expected, DSB repair frequencies in IM-treated cells were significantly decreased (P 5 0.0055) ( Figure 2D ). Expression of RAD51SM also caused a reduction in DSB repair in mock-treated cells, however, without reaching statistical significance (P 5 0.1163). After IM treatment, DSB repair frequencies were not further reduced by RAD51SM, which could be due to the fact that the values were already close to the detection limit of $2 Â 10 À5 . When comparing DSB repair between K562(D3#)/RAD51SM cells without and with IM treatment, kinase inhibition significantly downregulated repair frequencies despite RAD51 inactivation (P 5 0.0345). These results supported the conclusion drawn from the experiments with Mo7e and MBA in K562 cells, indicating that the kinase BCR-ABL significantly stimulates homologous DSB repair, whereby RAD51-independent, and, therefore, errorprone mechanisms seem to play a major role. Moreover, use of extrachromosomal and intrachromosomal DSB repair substrates showed that the effect is largely independent of chromatin components, emphasizing the potential involvement of proteins of the DSB repair machinery itself.
BCR-ABL downregulates MDC1 and 53BP1 and enhances CtIP levels in response to irradiation Because BCR-ABL appeared to enhance both microhomology-and homology-directed error-prone DSB repair processes through direct regulation of DSB repair components, we next monitored expression of critical factors involved in the initiation of these repair mechanisms and/or pathway choice: MDC1, 53BP1 and CtIP (13, 32, 33) . In Figure 3 , we show expression of MDC1, 53BP1 and CtIP proteins, as a function of the BCR-ABL status and in response to DSB-inducing treatment.
We comparatively analyzed protein levels in enriched nuclear extracts from Mo7e and MBA cells ( Figure 3A ) and in whole-cell extracts from K562 cells 24 h after the following treatments ( Figure 3B ): Mo7e and MBA were irradiated with a dose of 6 Gy, and MBA was further treated with IM for 24 h followed by mock or radiation treatment. K562 cells were exposed to IM or solvent. Higher protein amounts of 53BP1 and MDC1 were detected in Mo7e in comparison with MBA cells regardless of irradiation. IM treatment of MBA cells reconstituted 53BP1 protein to similar levels as detected in the parental Mo7e line. Differently, recovery of protein accumulation by IM was not observed for MDC1. When we examined phosphorylation of 53BP1 on Serine 25, which represents a signaling event catalyzed by ATM (33,34) with potential relevance for 53BP1's functions in response to DNA damage (35), we noticed phosphorylation in response to IR in Mo7e but not MBA cells both without and with IM treatment. Because phosphorylation of Serine 25 on 53BP1 was reported to correlate with 53BP1 foci formation (35), we wanted to understand whether lack of Serine 25 phosphorylation in MBA cells abrogated the formation of 53BP1 foci in the nucleus. When we tested the capacity of 53BP1 foci formation in Mo7e and MBA cells in response to the DNA-damaging agent Mitomycin C, we counted 14.4 foci per cell for Mo7e and 6.8 for MBA (supplementary Figure 1 is available at Carcinogenesis Online). Thus, 53BP1 foci assembly was still functional in MBA cells but the number of foci was reduced, reflecting reduced 53BP1 protein expression. CtIP protein levels rose in MBA compared with Mo7e cells particularly after IR ( Figure 3A) . Treatment of MBA cells with IM completely abrogated CtIP protein accumulation. Corresponding regulation of CtIP messenger RNA was found in real-time quantitative polymerase chain reaction analyses, indicating transcriptional upregulation of CtIP expression after IR in In K562 cells, we did not observe changes in the 53BP1 or MDC1 protein levels after incubation with IM. In contrast, CtIP expression was almost completely lost in response to IM treatment ( Figure 3B ). As the expression of CtIP was enhanced in MBA, especially after irradiation, and was abolished in response to IM in MBA and K562 cells, CtIP became a candidate mediator of DSB repair regulation by BCR-ABL. The possibility that loss of MDC1 or 53BP1 accumulation in MBA versus Mo7e cells abolished a mechanism antagonizing BCR-ABL-mediated stimulation of SSA was less probably from the lack of expression changes in IM-versus mock-treated K562 cells, as these reproduced the DSB repair phenotype in Mo7e versus MBA.
CtIP is required for the upregulation of SSA by BCR-ABL kinase activity To test whether CtIP is implicated in SSA enhancement, which we consistently observed in cells with BCR-ABL kinase activity, CtIP expression was silenced by RNA interference in Mo7e and MBA cells. Thus, we transfected these cells with the SSA plasmid reporter 5#EGFP/HR-EGFP, concomitantly with I-SceI expression and pRSshCtIP knockdown plasmid. In parallel, we utilized D-EGFP/3#EGFP substrate for combined HR and SSA analysis. As before, MBA cells showed significantly enhanced DSB repair by SSA compared with Mo7e cells (P 5 0.0083) ( Figure 4A ). Strikingly, silencing of CtIP expression completely abrogated SSA enhancement in MBA versus Mo7e cells (P 5 0.0568), i.e. led to a decrease of the elevated DSB repair frequencies in MBA (P 5 0.0191) without a significant effect on Mo7e (P 5 0.2231). Figure 4B shows that the same pattern of DSB repair regulation by BCR-ABL arose when we used DNA substrate D-EGFP/3#EGFP, which was in agreement with our observation from Figure 1C that in MBA cells this substrate is utilized for SSA exclusively rather than for HR plus SSA. Efficient knockdown of CtIP expression was verified by immunoblotting as is shown in Figure  4C . These results suggested that CtIP is required for the upregulation of SSA by BCR-ABL.
To confirm these results in a different cell type, we performed knockdown experiments directed against CtIP in K562(D3#) CML cells carrying chromosomally integrated substrate D-EGFP/3#EGFP. As before, BCR-ABL kinase activity was inhibited by treatment with IM for 24 h. Subsequently, cells were subjected to DSB repair analysis by transfection with I-SceI plasmid. Controls were cotransfected with empty pRS plasmid and the knockdown samples with pRS-shCtIP plasmid. Evaluation of DSB repair frequencies 48 h after transfection showed that DSB repair in K562(D3#) was significantly diminished (P 5 0.0289) after IM exposure ( Figure 5A-C) . Silencing of CtIP expression in K562(D3#) caused a decrease of DSB repair (P 5 0.0243) to a similar extent as was observed in IM-treated cells ( Figure 5A ). No significant difference was observed between mock-and IM-treated cells when CtIP was silenced (P 5 0.7688). This result provided further evidence for the importance of CtIP in promoting homologous DSB repair downstream of the BCR-ABL kinase. For comparison, BCR-ABL stimulates mutagenic homologous DNA DSB when we used RNA interference directed against MDC1 or 53BP1, DSB repair was not significantly altered and IM exerted a similar downregulation of the repair frequencies as without silencing of MDC1 or 53BP1 ( Figure 5B and C) . Efficient knockdown of CtIP, MDC1 and 53BP1 expression in K562(D3#) can be deduced from the immunoblots in Figure 5D .
Several lines of evidence have pointed to a critical role of CtIP in promoting DNA resection at DSBs to enable homologous DSB repair (36, 37) . SSA requires the generation of single-stranded overhangs on DNA ends by an exonuclease, and these ssDNA ends are subsequently coated by RPA (replication fork protein A). The respective exonuclease function and the recruitment of RPA have been attributed to CtIP (37) .
To investigate the dynamic of RPA foci formation in Mo7e and MBA cells, both cell lines were treated with the radiomimetic drug bleomycin for the generation of DSBs. After 1, 3 and 6 h of treatment, the cells were fixed and immunofluorescence analysis was performed with antibodies directed against RPA ( Figure 6B ). After 1 h of treatment, an average number of 10.7 foci per cell was counted in Mo7e and 16.2 foci per cell in MBA cells by automated quantification (Figure 6A) . After 3 h of treatment, 15.7 versus 27.9 and after 6 h, 19.3 versus 27.6 foci were quantified in Mo7e and MBA, respectively. In summary, elevated RPA foci formation was detected in MBA cells at all time points after the generation of DSBs, which is consistent with CtIP activation by BCR-ABL, i.e. a prerequisite for SSA enhancement. 
Discussion
Accumulating evidence has associated the constitutive tyrosine kinase activity of BCR-ABL with genomic instability observed in patients at advanced stages of CML as well as in human cell line and animal models of the disease. Nevertheless, the mechanisms underlying this instability have been discussed controversially and the molecular components involved remained to be elucidated (31) .
In the present study, we performed DSB repair analysis using a series of distinct DNA repair substrates in a human megakaryocytic and CML cell lines to directly compare the influence of BCR-ABL on different pathways. The results showed an increase in mutagenic DSB repair, namely in MMEJ and SSA, in the BCR-ABL-positive cell line, MBA, in comparison with its isogenic, BCR-ABL-negative counterpart, Mo7e. These results are in agreement with previous data, indicating higher SSA frequencies in murine BCR-ABL-positive cell lines (17, 18) . They are also consistent with reports on the downregulation of the canonical NHEJ factors DNA-PKcs, Artemis and LigaseIV in human BCR-ABL-positive cell lines, which was accompanied by a shift to the error-prone alternative NHEJ pathway (19, 20, 38) . However, in apparent contradiction to previous studies employing murine cell lines, in which BCR-ABL was proposed to stimulate HR (22, 24) , we measured similar HR frequencies in Mo7e and MBA cells independently of the length of homology between the sequences undergoing DNA exchange, i.e. independently of the fidelity of the HR process (26) . Since there are major differences between distinct DSB repair activities and DNA damage responses in rodents and man (39, 40) , it is conceivable that species differences explain the divergent results obtained.
Once we had established that the mutagenic SSA pathway was upregulated, we searched for protein factors that are necessary for this process and could be mediators of BCR-ABL's influence. In the light of our and previous findings (17) (18) (19) (20) 38) , we chose to investigate proteins acting at the initial branchpoints in the response to a DSB. In this context, MDC1 and 53BP1 were interesting owing to their distinct roles in recruiting HR and NHEJ proteins, respectively, to the DSB (8, 32) . Additionally, 53BP1 was shown to regulate the choice between canonical and alternative NHEJ during class switch recombination (41) . CtIP has been positioned at the intersection between canonical NHEJ versus alternative NHEJ and homologous DSB repair, the latter of which depends on extensive DNA end resection and ssDNA formation (9) .
The accumulation of CtIP protein in MBA, and its loss after IMmediated BCR-ABL kinase inhibition, also observed in the K562 cell line, indicated that BCR-ABL kinase activity is involved in the positive control of CtIP expression. Applying RNA interference, we found that CtIP is necessary for the stimulation of SSA in the BCR-ABL-positive human cell lines MBA and K562. SSA activities in the BCR-ABL-negative Mo7e cell line or in IM-treated K562 cells were not altered, suggesting that CtIP specifically mediates BCR-ABLdependent mutagenic DSB repair. For comparison, silencing of ERCC1, a key protein in the SSA pathway (16), caused downregulation of SSA frequencies already in Mo7e (data not shown), i.e. independently of BCR-ABL. Augmented RPA foci accumulation in MBA, as a measure of ssDNA generation, i.e. CtIP function (9), provides further evidence for functional activation of CtIP by BCR-ABL. These observations provide a mechanistic basis for the observed BCR-ABL-mediated upregulation of the error-prone DSB repair mechanisms SSA and MMEJ, also called micro-SSA, because both pathways require initial end trimming by CtIP (13) . The question remains as to why HR, a process which also relies on DSB end processing by CtIP, appears to be less affected by BCR-ABL than by SSA. In this context, it is interesting that BRCA1 interacts and ubiquitinates CtIP in response to DSBs, thereby recruiting CtIP to the lesion and promoting HR (42, 43) . However, depending on the post-translational modifications, CtIP can exert different functions. Lack of phosphorylation of Serine 327 in CtIP by CDK abolishes its interaction with BRCA1 and directs CtIP function to MMEJ (13, 42) . As BRCA1 is downregulated in BCR-ABL-positive human cells (25) and because BRCA1 deregulation shifts the DSB repair pathway choice from HR to the mutagenic DSB repair pathways SSA and MMEJ (44), we propose that lack of BRCA1 and thereby BRCA1-CtIP complex formation compromise enhancement of HR by BCR-ABL.
Our data further showed that two other putative BCR-ABL targets, MDC1 and 53BP1, displayed lower protein amounts in MBA than in Mo7e cells. In K562 cells, IM treatment did, however, not cause a major change in the protein levels, even though in MBA cells, treated with IM, 53BP1 protein reaccumulated. Nevertheless, 53BP1 re-accumulation in MBA was not accompanied by a reconstitution of 53BP1 phosphorylation on Serine 25 after irradiation, an event catalyzed by ATM. 53BP1 foci formation at DSB sites had been correlated in the literature with Serine 25 phosphorylation (35), but in our work, damage-inducible 53BP1 foci formation was detectable in MBA cells, at least to the extent expected from the reduced 53BP1 protein levels. The work from Munoz et al. (45) has further shown that phosphorylation of Serine 25 in 53BP1 is required for 53BP1 to act as an adaptor protein for ATM and for inducible interactions of 53BP1 with hPTIP, a regulator of cellular responses to DNA damage. Therefore, a kinase activity-independent effect of the BCR-ABL protein on the destabilization of the genome, namely via repression of Serine 25 phosphorylation on 53BP1, is conceivable and will have to be addressed in future investigations. Recent reports revealed that 53BP1 counteracts error-prone NHEJ and homologous DSB repair in BRCA1-deficient cells by blocking resection of DNA breaks (41) . Thus, even though 53BP1 knockdown did not further influence the stimulatory effect of BCR-ABL kinase activity in K562 cells, BCR-ABL-mediated downregulation of 53BP1 might be coupled to CtIP upregulation to assure fully efficient DSB repair. Similarly, silencing of MDC1 in K562 cells did not significantly change the enhancement of homologous DSB repair by the BCR-ABL kinase activity. Nevertheless, MDC1 is required for BRCA1 recruitment to DSBs (32) , so that the reduction of MDC1 levels by BCR-ABL might exacerbate the consequences of BRCA1 downregulation in promoting error-prone DSB repair pathways rather than HR.
In this work, we have shown that BCR-ABL promotes mutagenic DSB repair rather than comparatively high-fidelity mechanisms, such as HR, thereby accelerating the process of malignant transformation. We identified CtIP as a key downstream target of BCR-ABL-mediating error-prone SSA repair and very probably also accelerated end processing. Importantly, enhancement of DSB resection highly increases the probability of acquiring mutations in the DNA stretches surrounding DSBs (46, 47) , which can be a source of mutation accumulation in CML. Supplementary Figures 1 and 2 
Supplementary material
